Management and Advisory Board
Inmedix team members bring decades of combined experience within
Inmedix team members bring decades of combined experience within
Co-Founder & Chief Executive Officer
Dr. Holman is the founding rheumatologist at Pacific Rheumatology Associates Inc PS, Director of Research at Pacific Rheumatology Research Inc., a former President of the Northwest Rheumatism Society (2005) and a Clinical Associate Professor of Medicine at the University of Washington. He has 25 year clinical and 19 year rheumatology research career experience with 16 lead author published papers, 25 lead author published abstracts. For Inmedix, he has designed, completed and published 15 clinical studies, including FDA negotiations, involving nearly 1500 patients.
Research highlights include discovering and licensing use of dopamine agonists as a treatment of fibromyalgia, applying autonomic nervous system (ANS) analysis with heart rate variability (HRV) to elevate treatment remission rates in patients with rheumatoid arthritis and other autoimmune diseases, and broadening understanding of pain in patients with PC3 (positional cervical cord compression) using dynamic cervical magnetic resonance imaging (dMRI).
Mr. Sciarrillo has been a C-level Executive for 25+ years in mid and small entrepreneurial companies in the manufacturing, management consulting and real estate industries. He was lead negotiator for Inmedix's historic sale of its method-of-use patents for treatment of fibromyalgia with dopamine agonists in 2007. He is also CEO of The New England Group, a management consulting firm founded by him in 1989. Tim’s professional experience also includes many years at the accounting firm Deloitte, Haskins & Sells as both an employee and a consultant to the C-level executives. He graduated from the College of the Holy Cross with a degree in Physics.
Chief Operating Officer
Prior to joining Inmedix, Steven was part of the executive management team of Light Sciences Oncology, a private venture-backed biotechnology company that raised over $250 Million to develop a combinational product (drug and device) for the treatment of cancer and other indications. Over his 17 years at Light Sciences Oncology Steven held positions with escalating responsibility from design engineering, product development, non-clinical research, business development and licensing, market research, and corporate strategy and development. He was intimately involved in the growth of Light Sciences from the startup phase through late stage clinical testing and eventual out-licensing of the technology. Light Sciences investigated and researched its proprietary platform technology in 7 Phase 1 Studies, 5 Phase 2 Studies, and 2 Phase 3 Studies within 3 separate IND’s. Steven holds a B.S. in Materials Science Engineering (Ceramic Engineering), M.S. in Bioengineering (Medical Engineering), and an M.B.A. from the University of Washington.
VP, Corporate Development
Stuart Hwang is a corporate development professional with more than 20 years in drug and diagnostic development. He has had extensive experience in developing strategic partnerships and fundraising with a cumulative transaction value greater than $2B. Prior to Inmedix, he has had an active advisory practice as a consultant and in investment banking supporting emerging and established biotech companies develop and execute on corporate strategy and transactions including partnerships, licensing, fundraising and M&A. Earlier, he led business development at Astex (acquired by Otuska). Prior to that he held business development leadership roles at Perlegen and Agilent. He has led drug and diagnostic R&D teams at SuperGen, Cor Therapeutics, Millennium, Celera, Agilent and at UCSF/LBNL supporting 7 NME INDs and the development of 3 marketed drugs. He developed deep sequencing and genome partitioning algorithms (founding scientist, Celera Genomics) and several first whole genome arrays (Agilent) and partnered with pharma/biotech to integrate these novel approaches into drug development. Stuart is an inventor on several patents, authored 20 journal articles and presented at numerous global scientific and business conferences. He received a BA, High Honors at UCSC and a Ph.D. in Endocrinology at UC Berkeley, Cancer Research Lab (NCI Fellowship). He completed his post-doctoral work with Dr. JW Gray at UCSF & LBNL as a Distinguished Human Genome Postdoctoral Fellow (DOE).
Director, Finance & Reimbursement
In her years as a C-level executive and consultant, Glynis has advised on, implemented, and led: Conflict Resolution,
Glynis also enjoys writing, teaching and giving talks to attorneys and physicians, as well as residents and fellows at the UW Medical Center.
Education Program Director
For 25 years, Rae is a renowned patient and physician educator in the field of rheumatology, pain and fibromyalgia and has collaborated with Dr. Holman for over 15 years. She helped create the National Fibromyalgia Research Association (NFRA) in 1992 and served as its Executive Director for 14 years, organizing 5 international research symposiums and numerous exhibitions at national meetings. She has served as an FDA patient representative, a participant in NIH policy meetings, the Executive Director of the National Fibromyalgia Association, the Medical Education and Research Director for the National Fibromyalgia and Chronic Pain Association, and most recently, the Executive Director of the International Myopain Society.
Manager, Inmedix UK, Ltd.
Daniel heads commercialization, academic and research coordination efforts in the United Kingdom and Europe through our subsidiary, Inmedix UK, Ltd. He joins Inmedix after a long research association with Dr. Holman in the field of fibromyalgia. He has an elite sports background as well as pharmaceutical commercialization expertise at Baxter Healthcare as a sales representative and accounts/contract manager and as a regional development executive at BUPA (now Spire) Health Services. Daniel has intimate familiarity with rheumatology clinical practice. For nearly twenty years, he was clinic manager for the UK FM/ME Clinics working with Professor John E. Davies, MD, as well as providing private practice marketing/business consultancy and management at the Fibromyalgia Clinic, Harley Street, London. BS, Florida State University.
John R. and Eileen K. Reidman Professor of Medicine at Harvard Medical School and the R. Bruce and Joan M. Mickey Distinguished Chair in Rheumatology at the Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. 2000-01 President of the American College of Rheumatology.
William Bruce Professor and Vice Chair, Internal Medicine, Chief Division of Rheumatology, University of Nebraska Medical Center; 2012-13 President of the American College of Rheumatology
James W. Raitt MD Professor of Medicine, Stanford University, Co-Chief Division of Immunology & Rheumatology, Stanford University School of Medicine
Professor of Medicine, University of Toronto; Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital
Biopharmaceutical consultant and Adjunct Clinical Professor of Medicine, Stanford University School of Medicine
Carl M Pearson Professor Emeritus, UCLA School of Medicine, University of Washington, University of Florence, Italy
Panel member Western Institutional Review Board, Puyallup, WA. Former head, Tacoma Center for Arthritis Research conducting 250 clinical research trials over 35-year research career
Head of Rheumatology and Translational Research at the Institute of Infection and Immunity and Director of the Cardiff Regional Experimental Arthritis Treatment and Evaluation (CREATE) Centre at Cardiff University School of Medicine
Professor of Musculoskeletal Sciences at the University of Oxford and Director of Clinical Sciences at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences and chairs the NOCRI Translational Research Partnership
Professor of Medicine at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Vice Chairman of the Department of Rheumatic and Immunological Diseases, Co-director of the Center for Vasculitis Care and Research, and Director of the Cleveland Clinic's RJ Fasenmyer Center for Clinical Immunology at the Cleveland Clinic in Cleveland, Ohio.
Currently an independent consultant, Dick is a respected business development and licensing professional with an extensive track record of success in domestic and international business development and licensing in the pharmaceutical, biotech, and drug delivery industries.
Dr. Welter’s previous biotech and small company experience includes positions as Vice President of Business/Corporate Development at Euthymics Biosciences (Neurovance), CIMA Labs (drug delivery), VioQuest and Vela Pharmaceuticals. In those positions, he was responsible for leading all licensing and business development activities, including the direction and coordination of financial, marketing, legal, and regulatory evaluations of compound opportunities. Dick’s experience in the pharmaceutical industry includes 24 years of service with Pharmacia Corporation (and its heritage companies, beginning at Upjohn), where he last served as Executive Director of Global Licensing, primarily responsible for CNS worldwide.
Biostatistics & Regulatory
Edmund has been a co-author with Dr. Holman on pivotal Inmedix studies for nearly 10 years. He is an independent statistical consultant with over 16 years of experience in the pharmaceutical and biotech industry. In the first 6 years of his career, Edmund was a Senior Statistician responsible for a rheumatoid arthritis clinical program at Amgen and Associate Director responsible for various oncology clinical programs at Cell Therapeutics. Since forming his own consulting business, Edmund has provided a wide range of statistical services for a number of pharmaceutical and biotech companies in various disease areas including oncology, hematology, autoimmune diseases and medical devices. Edmund's primary areas of expertise are clinical trial designs, statistical research and analysis, statistical programming development, and regulatory submissions.
As an independent consultant, Chris led both face-to-face meetings with FDA and continues to lead Inmedix in US and EU/UK regulatory affairs. He has over twenty-five years of regulatory, quality and clinical affairs industry management experience in FDA CDRH and CBER regulated IVD devices, especially in infectious disease tests, including HIV and also autoimmune disease tests. He is a member of the AdvaMed IVD Taskforce, AMDM Board, RAC and a RAPS Fellow as well as guest lecturer at University of Washington Masters Degree Program in Regulatory Affairs.
At Bio-Rad for 15 years, he was a Regulatory Affairs, Quality Assurance and Clinical Affairs Manager, responsible for U.S. FDA submissions, including BLA's, IND's, PMA's, IDE's, 510(k)'s for IVD products; CE marking of List A and List B products; clinical trials for above submissions and overall quality assurance responsibilities.
As Senior Council at Cooley, LLP in Palo Alto, Barclay has made pivotal contributions to Inmedix technology licensing efforts. He represents biotechnology, medical technology, digital health and other life sciences companies in a broad range of corporate and financial matters, with deep experience in transactions involving intellectual property. Much of his practice is devoted to negotiating and drafting corporate partnership agreements, licensing arrangements, strategic alliances, joint venture agreements and other complex technology transactions. Barclay also provides general representation of technology companies in corporate law, venture capital financings, private placements, asset sales and other strategic transactions involving his clients.
Blake has been instrumental in converting Inmedix LLC to Inmedix Inc. and in designing our capital funding strategy. As a Partner and member of the Technology Companies Group in the Seattle office of Orrick, Herrington & Sutcliff, LLP, his practice focuses on advising high-growth technology and life sciences companies and their founders, advisors and investors.
Blake brings a unique and invaluable mix of in-house, entrepreneurial, and law firm experience, having served as General Counsel and senior executive of a software company and two biotech companies (having co-founded one of them), as well as outside corporate counsel in elite AmLawGlobal 100 law firms. His experience spans multiple industries, including life sciences, software, hardware, mobile, fintech, cybersecurity, manufacturing, and retail. He has counseled high-growth companies on more than 200 venture capital and debt financings, more than 100 M&A transactions, and numerous public offerings, as well as service as a trusted advisor to management teams and Boards on both strategic and day-to-day matters.
Blake is proud to have worked with a variety of technology and life science companies, venture capital firms and investment banks, including A Place for Mom (acquired by Warburg Pincus), Amazon.com (Nasdaq: AMZN), Barclays, Cloudhopper (acquired by Twitter; NYSE: TWTR), Critical Informatics, Deutsche Bank, fatfoogoo (sold to Digital River; Nasdaq: DRIV), Ikaria, IronPort Systems (acquired by Cisco; Nasdaq: CSCO), Kineta, KITE Solutions, Oculus (Nasdaq: FB), Qpass (acquired by Amdocs; NYSE: DOX), SeaPoint Ventures, Square Enix, Storm Ventures, Targeted Growth, TIBCO Software (Nasdaq: TIBX), U.S. Venture Partners, Xcyte Therapies, Zumobi, and Zipwhip.
Prior to his legal career, Blake served with distinction in the U.S. Navy as a Surface Warfare Officer, including two combat deployments to the Persian Gulf, where he was decorated for his performance during Operations Southern Watch and Desert Strike.